This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ho, C.-L. Articles by Shih, I.-M. Search for Related Content PubMed PubMed Citation Articles by Ho, C.-L. Articles by Shih, I.-M.

Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors

Departments of ¹ Pathology, ² Oncology and Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland

Molecular genetic changes that are associated with the initiating stage of tumor development are important in tumorigenesis. Ovarian serous borderline tumors (SBTs), putative precursors of low-grade serous carcinomas, are among the few human neoplasms with a high frequency of activating mutations in BRAF and KRAS genes. However, it remains unclear as to how these mutations contribute to tumor progression. To address this issue, we compared the mutational status of BRAF and KRAS in both SBTs and the adjacent epithelium from cystadenomas, the presumed precursor of SBTs. We found that three of eight SBTs contained mutant BRAF, and four SBTs contained mutant KRAS. All specimens with mutant BRAF harbored wild-type KRAS and vice versa. Thus, seven (88%) of eight SBTs contained either BRAF or KRAS mutations. The same mutations detected in SBTs were also identified in the cystadenoma epithelium adjacent to the SBTs in six (86%) of seven informative cases. As compared to SBTs, the cystadenoma epithelium, like ovarian surface epithelium, lacks cytological atypia. Our findings provide cogent evidence that mutations of BRAF and KRAS occur in the epithelium of cystadenomas adjacent to SBTs and strongly suggest that they are very early events in tumorigenesis, preceding the development of SBT.

This article has been cited by other articles:

				W G McCluggage My approach to and thoughts on the typing of ovarian carcinomas J. Clin. Pathol., February 1, 2008; 61(2): 152 - 163. [Abstract] [Full Text] [PDF]

				H.-C. Yeh, Y.-P. Ho, I.-M. Shih, and T.-H. Wang Homogeneous point mutation detection by quantum dot-mediated two-color fluorescence coincidence analysis Nucleic Acids Res., March 3, 2006; 34(5): e35 - e35. [Abstract] [Full Text] [PDF]

				I.-M. Shih and R. J. Kurman Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges Clin. Cancer Res., October 15, 2005; 11(20): 7273 - 7279. [Abstract] [Full Text] [PDF]

				Y.-Z. Feng, T. Shiozawa, T. Miyamoto, H. Kashima, M. Kurai, A. Suzuki, and I. Konishi BRAF Mutation in Endometrial Carcinoma and Hyperplasia: Correlation with KRAS and p53 Mutations and Mismatch Repair Protein Expression Clin. Cancer Res., September 1, 2005; 11(17): 6133 - 6138. [Abstract] [Full Text] [PDF]

				N. M.G.M. Appels, J. H. Beijnen, and J. H.M. Schellens Development of Farnesyl Transferase Inhibitors: A Review Oncologist, September 1, 2005; 10(8): 565 - 578. [Abstract] [Full Text] [PDF]

				G. Pohl, C.-L. Ho, R. J. Kurman, R. Bristow, T.-L. Wang, and I.-M. Shih Inactivation of the Mitogen-Activated Protein Kinase Pathway as a Potential Target-Based Therapy in Ovarian Serous Tumors with KRAS or BRAF Mutations Cancer Res., March 1, 2005; 65(5): 1994 - 2000. [Abstract] [Full Text] [PDF]